Phase 2 N=83 Neuromuscular Blockade for Post-Cardiac Arrest Care
Cardiac Arrest
Primary: Change in Lactate Over 24 Hours — -2.2; -2.3 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Waldenstrom's Macroglobulinemia
Primary: Overall Response Rate — 47 percentage of participants
Phase 2 N=158 Revacept in Symptomatic Carotid Stenosis
Carotid Stenosis · Atherosclerosis · Stroke
Primary: New DWI Lesion(s) — 1.2; 1.0; 0.6 Number of new lesions
Phase 2 N=25 A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)
Chronic Hepatitis B
Primary: Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV — 7.91; 8.03; -4.45; -3.30 Log10…
Phase 2 N=32 A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 27; 18; 20; 15 Participants
Phase 2 N=82 Exenatide Once Weekly for Smoking Cessation
Smoking Cessation
Primary: Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm — 19; 11 Participants
Phase 2 N=114 Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Colon Staining in Preparation for Colonoscopy
Primary: Evaluation of Mucosal Staining Efficacy — 6.8; 2.3; 8.1; 7.0 scores on a scale
Phase 2 N=76 A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 3; 7; 10 participants
Phase 2 N=73 A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
Chronic Hepatitis B
Primary: Change in Mean log10 Serum HBsAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC — 3.48; 3.57; 2.99; 3.35 Log10 International…
Phase 2 N=227 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Cachexia
Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…
Phase 2 N=20 An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Primary: Reported Change in Seizures Frequency From Baseline at 13 Weeks — 4.4; 189.5 seizures/two weeks
Phase 2 N=320 Immunogenicity and Safety of a Purified Vero Rabies Vaccine
Rabies Virus
Primary: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus at Day 0 — 0.101; 0.100; 0.102; 0.101 international units per milliliter
Phase 2 N=46 Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Phase 2 N=30 Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Breast Cancer
Primary: Progression-free Survival — 4.9 months
Phase 2 N=34 Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3])
Parkinson's Disease
Primary: Gait Speed — 121.27; 124.89 cm/s — p=0.003